Phase 2 N=99 RN624 For Pain Of Post-Herpetic Neuralgia
Neuralgia, Postherpetic
Primary: Change From Baseline in Average Daily Pain Numeric Rating Scale (NRS) Score at Week 6 — 6.40; 6.42; 6.39; -1.22 units on a scale — p=0.687
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=222 Pregabalin for Treatment of Patients With Postherpetic Neuralgia (PHN)
Postherpetic Neuralgia ( PHN )
Primary: Baseline Mean Pain Score — 5.93; 6.08 units on a scale
Phase 2 N=294 A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia
Neuralgia, Postherpetic
Primary: Change From Baseline in the Average Pain Intensity Score at Week 12 — 6.13; 6.04; 6.05; -1.42 Score on a scale
N/A N=765 DS-5565 Phase III Study for Post-herpetic Neuralgia
Post-Herpetic Neuralgia
Primary: Change in the Average Daily Pain Score (ADPS) From Baseline to Week 14 Following Oral Administration of DS-5565 in Asian Participants With Post-herpetic Neuralgia…
Phase 3 N=452 Safety and Efficacy of Gabapentin in Postherpetic Neuralgia
Neuralgia,Postherpetic
Primary: Mean Change in Baseline Observation Carried Forward (BOCF) Average Daily Pain Score — -2.12; -1.63 Scores on a scale — p=0.0125
Phase 2 N=187 Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)
Postherpetic Neuralgia
Primary: Primary Endpoint Will be the Change From Baseline in Average Pain Score Over the Last 7 Days of the Maintenance Phase. — -2.65; -2.22 Scores on a scale — p=0.2537
N/A N=101 Burden of Herpes Zoster and Post-herpetic Neuralgia Among People ≥ 50 Years Old in France
Herpes Zoster
Primary: Evaluation of Herpes Zoster (HZ) and Postherpetic Neuralgia (PHN) Related Direct Medical Costs by Drugs Prescribed. — 10; 1; 3; 0 Participants
Phase 3 N=372 A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
Neuralgia, Postherpetic
Primary: Mean Pain Scores at Endpoint — 5.12; 4.81; 4.26; 4.49 score on scale — p=0.262
Phase 2 N=376 A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)
Neuralgia, Postherpetic
Primary: Change From Baseline in the Mean 24-hour Average Pain Intensity (API) Score at the End of Maintenance Treatment (EOMT) Using Last Observation Carried Forward (LOCF) Data…
Phase 2 N=300 A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN)
Postherpetic Neuralgia
Primary: Change From Baseline to Week 4 in the Weekly Average of the Daily Average Numeric Rating Scale (NRS) Pain Scores Using a Mixed Model for Repeated Measures — 5.37; 5.60…
Phase 3 N=806 Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia
Post Herpetic Neuralgia
Primary: Number of Participants With Loss of Therapeutic Response. — 29; 63 Participants — p=<0.0001
Phase 2 N=146 Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)
Neuralgia
Primary: Change From Baseline in Average Pain Scores to Week 15/ End of Treatment (EOT) (Including Modified BOCF Data) — -0.55; -1.30; -0.95; -0.50 Scores on a scale
Phase 2 N=72 A Study To Compare Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia
Postherpetic Neuralgia
Primary: Mean Pain Score on Daily Pain Rating Scale (DPRS) — 4.32; 4.22; 5.57 units on a scale — p=0.3910
Phase 4 N=121 Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP
Diabetic Peripheral Neuropathic Pain (DPN) · Postherpetic Neuralgia (PHN) · HIV-related Neuropathic Pain (HIV)
Primary: Change From Baseline to End of Treatment (EOT) in Weekly Mean Pain Score on the Daily Pain Rating Scale (DPRS) — -3.8 scores on scale — p=< 0.0001
Phase 2 N=70 A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)
Postherpetic Neuralgia
Primary: Change in Mean Daily Pain Score From Baseline to Week 3 (With LOCF) — -0.94; -0.97 units on a scale
Phase 2 N=360 A Comparison of EpiCept™ NP-1 Topical Cream vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)
Post Herpetic Neuralgia · PHN · Neuropathy
Primary: Change in Pain Scores Comparing NP-1 Cream vs. Placebo Cream for Treatment of the Pain of Post Herpetic Neuralgia(PHN)From Baseline to 28 Days. — 2.424; 2.471; 1.877…
Phase 3 N=126 A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Postherpetic Neuralgia
Neuralgia, Postherpetic
Primary: Summary of Adverse Events — 124; 14; 5; 17 subjects
Phase 2 N=152 A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)
Neuralgia, Postherpetic
Primary: Percentage Change in Average Pain Intensity Score From Baseline to the Last Week of the 4-week Treatment Period — -26.16; -26.11; -27.36 percentage of change — p==0.965
Phase 2 N=79 Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia
Postherpetic Neuralgia
Primary: Change From Baseline (Week 2 of the Run-in Period) in Average Daily Pain Score (ADPS) — -1.62; -2.42 score on a scale — p=0.120
Phase 2 N=567 Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia
Postherpetic Neuralgia
Primary: Change in Mean Pain (NRPS) From Baseline to Endpoint in Mean Pain — -1.9447; -1.9786; -1.6798; -1.6633 Points
Phase 1 N=35 The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012)
Postherpetic Neuralgia
Primary: Change From Baseline in Pain Intensity at Week 4 of Each Treatment Period — -1.776; -1.263 Score on a scale — p=0.075
Phase 3 N=262 Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)
Neuralgia
Primary: Mean Change From Baseline in Short Form-McGill Pain Questionnaire (SF-MPQ): Sensory and Affective Scores, From Baseline to Week 48. — -10.5; -8.1; -9.0; -9.8 Scores on a…
N/A N=394 Study to Estimate the Burden of Herpes Zoster (HZ) and Post-herpetic Neuralgia (PHN) in Italy
Herpes Zoster · Herpes Zoster Vaccine
Primary: Overall Incidence Rate of Herpes Zoster (HZ) Cases, by Age and Gender — 5.19; 6.29; 5.00; 9.19 Number of HZ cases/1000 person-years
Phase 2 N=96 A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
Neuralgia, Postherpetic
Primary: Change From Baseline in the Mean 24-hour Average Pain Intensity (API) Score at the Last Week of Each Treatment Period Using Last Observation Carried Forward (LOCF) Data…
N/A N=197 Phase IV Study of FDA Approved, Once-Daily GRALISE™(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia
Post Herpetic Neuralgia
Primary: Change From Baseline to End of Study in LOCF VAS — -20.4; -21.3 scores on a scale
Phase 3 N=623 Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral Neuropathy
Diabetic Neuropathy, Painful
Primary: Baseline Mean Pain Score — 6.65; 6.67 units on a scale
Phase 3 N=256 Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.
Neuropathic Pain
Primary: Neuropathic Pain in Subjects With Peripheral Neuropathic Pain Conditions During the Double-blind Phase — 2.84; 3.62 score on scale — p=0.0018
Phase 2 N=91 A Phase 2 Study of Tapentadol Extended-Release (JNS024ER) ) in Japanese Participants With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia
Pain · Diabetic Neuropathies · Neuralgia
Primary: Change From Baseline in Average Numerical Rating Scale (NRS) Score at Week 12 — 6.7; 6.9; -2.6; -2.6 Units on a scale
Phase 3 N=258 A Confirmatory Study of Fentanyl in Participants With Post-herpetic Neuralgia, Complex Regional Pain Syndrome or Postoperative Pain Syndrome
Postherpetic Neuralgia · Complex Regional Pain Syndromes (CRPS) · Postoperative Pain
Primary: Time From the Initial Day of Application in Double-Blind Period to Withdrawal Because of Insufficient Analgesic Efficacy — NA; 45.0 Days — p=0.0003
N/A N=161 Symptom Management Efficacy Study to Reduce Distal Neuropathic Pain
Neuropathic Pain · HIV Neuropathy · HIV/AIDS
Primary: Gracely Pain Scale (GPS) — -2.51; -1.96; -2.38; -0.99 GPS pain score on a scale